HSA
CODX

Hussman Strategic Advisors’s Co-Diagnostics CODX Stock Holding History

Hussman Strategic Advisors’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,200
Closed -$53.3K – 302
2023
Q1 		$53.3K Hold
1,200
– – 0.01% 310
2022
Q4 		$90.7K Hold
1,200
– – 0.01% 287
2022
Q3 		$116K Hold
1,200
– – 0.02% 280
2022
Q2 		$202K Hold
1,200
– – 0.03% 287
2022
Q1 		$222K Hold
1,200
– – 0.04% 288
2021
Q4 		$321K Hold
1,200
– – 0.07% 276
2021
Q3 		$350K Hold
1,200
– – 0.08% 267
2021
Q2 		$297K Hold
1,200
– – 0.06% 301
2021
Q1 		$343K Buy
+1,200
New +$479K 0.07% 290

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
KOC
Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Hussman Strategic Advisors's CODX Position: Q2 2023 in Review

Hussman Strategic Advisors sold out of Co-Diagnostics (CODX) in Q2 2023, closing a stake of 1,200 shares — an estimated $53.3K sold.

Hussman Strategic Advisors first reported a position in CODX in Q1 2021 and held it in 9 quarters. The position peaked at $350K in Q3 2021. 43 funds tracked by Wall St. Rank hold CODX as of Q2 2023.

  • Hussman Strategic Advisors reported no remaining Co-Diagnostics position as of Q2 2023 after selling out during the quarter.
  • Hussman Strategic Advisors sold 1,200 Co-Diagnostics shares in Q2 2023, an estimated $53.3K.
  • Hussman Strategic Advisors first reported a position in Co-Diagnostics in Q1 2021 and held it in 9 quarters.
  • Hussman Strategic Advisors's Co-Diagnostics position peaked at $350K in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2023.

Based on Hussman Strategic Advisors's 13F filing for Q2 2023, filed 3 Aug 2023.